Edition:
India

ALK-Abello A/S (ALKb.CO)

ALKb.CO on Copenhagen Stock Exchange

1,728.00DKK
14 Nov 2019
Change (% chg)

kr.-30.00 (-1.71%)
Prev Close
kr.1,758.00
Open
kr.1,758.00
Day's High
kr.1,768.00
Day's Low
kr.1,720.00
Volume
9,251
Avg. Vol
13,758
52-wk High
kr.1,775.00
52-wk Low
kr.881.00

Latest Key Developments (Source: Significant Developments)

ALK-Abello: Member of Management Buys Shares For Total Of DKK 2.3 Mln
Monday, 11 Nov 2019 

Nov 11 (Reuters) - ALK-Abello A/S ::REG-REPORT ON TRANSACTIONS WITH ALK-ABELLÓ A/S B-SHARES AND ASSOCIATED SECURITIES BY MANAGERIAL STAFF.SØREN DANIEL NIEGEL, MEMBER OF MANAGEMENT, PURCHASED (EXERCISE OF SHARE OPTIONS) 5,000 ALK-ABELLO SHARES FOR TOTAL OF DKK 2,297,300.  Full Article

ALK-Abello Q3 EBITDA Up At DKK 36 Mln
Thursday, 7 Nov 2019 

Nov 7 (Reuters) - ALK-Abello A/S ::REG-NINE-MONTH INTERIM REPORT (Q3) 2019.Q3 TOTAL REVENUE WAS UP 11% IN LOCAL CURRENCIES AT DKK 739 MILLION (661)..Q3 TABLET SALES GREW BY 35% TO DKK 185 MILLION (138) AND COMBINED SCIT AND SLIT-DROPS SALES WERE UP 4%, REFLECTING CONTINUED RECOVERY OF SCIT SALES..Q3 OPERATING PROFIT (EBITDA) WAS DKK 36 MILLION (24) AND BENEFITED FROM HIGHER REVENUE AND OPERATIONAL EFFICIENCIES..FULL-YEAR OUTLOOK HAS BEEN UPDATED TO REFLECT IMPROVED EARNINGS AND PHASING OF INVESTMENTS.FULL-YEAR REVENUE IS STILL PROJECTED TO BE DKK 3,200-3,300 MILLION.THERE WAS GROWTH IN ALL SALES REGIONS, AT 6% IN EUROPE, 17% IN NORTH AMERICA AND 80% IN INTERNATIONAL MARKETS..OPERATING PROFIT (EBITDA) IS NOW EXPECTED AT DKK 200-250 MILLION (PREVIOUSLY DKK 150-250 MILLION).FREE CASH FLOW IN 2019 IS NOW EXPECTED AT APPROXIMATELY DKK MINUS 200 MILLION (PREVIOUSLY DKK MINUS 300 MILLION).DELIVER POSITIVE RESULTS DURING Q3, WITH BROAD-BASED GROWTH FROM ALL REGIONS.TABLET SALES GREW BY 35% AND PORTFOLIO WAS FURTHER STRENGTHENED BY ENCOURAGING FIRST LAUNCHES OF NEW TREE TABLET.IN FIRST NINE MONTHS OF YEAR, ALK SAW GROWTH OF 11% AND REMAINS ON COURSE TO DELIVER REVENUE GROWTH OF 10% OR MORE FOR FULL YEAR.IN FIRST MARKET, GERMANY, ALK HAS DELIVERED ITS BEST EVER TABLET LAUNCH IN TERMS OF PATIENTS AND SALES..IN NORTH AMERICA, WORK ON SLIT-TABLETS OPPORTUNITY CONTINUED TO DELIVER GRADUAL ACCEPTANCE AMONG KEY PRESCRIBERS, WITH IMPROVED PRESCRIPTION DEPTH THAT IS TRACKING CLOSE TO PLAN..  Full Article

ALK Secures Approval In Germany For Shorter Updosing Of Alutard SQ®
Monday, 14 Oct 2019 

Oct 14 (Reuters) - ALK-Abello A/S ::ALK-ABELLÓ A/S - ALK SECURES APPROVAL IN GERMANY FOR SHORTER UPDOSING OF ALUTARD SQ®.TODAY ANNOUNCED THAT IT HAS SECURED AN AMENDED REGULATORY APPROVAL IN GERMANY FOR ITS SUBCUTANEOUS ALLERGY IMMUNOTHERAPY (SCIT) PRODUCT ALUTARD SQ(®), ALLOWING A SHORTENED UPDOSING REGIMEN FOR PRODUCT.  Full Article

ALK-Abello: Chairman Steen Riisgaard To Step Down
Friday, 13 Sep 2019 

Sept 13 (Reuters) - ALK-Abello A/S ::CHANGE OF CHAIRMAN AT ALK.STEEN RIISGAARD, ALK'S CHAIRMAN OF BOARD, HAS INFORMED BOARD OF DIRECTORS OF HIS INTENTION TO STEP DOWN AT COMPANY'S NEXT ANNUAL GENERAL MEETING (AGM), IN MARCH 2020.BOARD OF DIRECTORS WILL PROPOSE NEW ELECTION OF ANDERS HEDEGAARD, CEO OF GERMAN-BASED RODENSTOCK GROUP AS NEW CHAIRMAN OF BOARD.  Full Article

ALK Announces New Epinephrine Auto-Injector Strategy For US
Friday, 9 Aug 2019 

Aug 9 (Reuters) - ALK-Abello A/S ::REG-ALK ANNOUNCES NEW EPINEPHRINE AUTO-INJECTOR STRATEGY BASED ON INNOVATIVE NEW PRODUCT FOR THE USA.ALK HAS ALREADY BEGUN TO SUPPORT DEVELOPMENT AND WILL SUBSEQUENTLY BE RESPONSIBLE FOR GLOBAL COMMERCIALISATION OF PRODUCT.NEW ANAPHYLAXIS STRATEGY IS TO BECOME A MAJOR PLAYER IN US EPINEPHRINE MARKET BASED ON AN EXCLUSIVE DEAL WITH WINDGAP MEDICAL TO LAUNCH A NEXT GENERATION EPINEPHRINE AUTO-INJECTOR PEN.NEW PEN IS DESIGNED TO BE SMALL, EASY-TO-USE, HEAT-STABLE, AND WITH A LONG SHELF LIFE.THIS ANNOUNCEMENT DOES NOT IMPACT ALK'S FINANCIAL GUIDANCE FOR 2019.HAS FINALISED ITS STRATEGY FOR ENTERING US MARKET FOR EPINEPHRINE (ADRENALINE) AUTO-INJECTORS (EAIS).  Full Article

ALK-Abello Submits Registration Application For Tree SLIT-Tablet In Canada
Monday, 24 Jun 2019 

June 24 (Reuters) - ALK-Abello A/S ::REG-ALK SUBMITS REGISTRATION APPLICATION FOR TREE SLIT-TABLET IN CANADA.ALK SUCCESSFULLY COMPLETED MARKETING AUTHORISATION PROCEDURE FOR ITS TREE SLIT-TABLET IN EUROPE EARLIER THIS MONTH AND EXPECTS PRODUCT TO BECOME AVAILABLE IN FIRST EUROPEAN MARKETS IN GERMANY AND SCANDINAVIA WITHIN THIS YEAR.IN CANADA AND EUROPE, TREE TABLET WILL BE A RELEVANT TREATMENT OPTION FOR RESPIRATORY ALLERGIES.  Full Article

ALK-Abello Q1 EBITDA Rises To DKK 133 Million
Thursday, 9 May 2019 

May 9 (Reuters) - ALK-Abello A/S ::REG-THREE-MONTH INTERIM REPORT (Q1) 2019.Q1 TOTAL REVENUE DKK 867 MILLION VERSUS DKK 752 MILLION YEAR AGO.Q1 EBITDA DKK 133 MILLION VERSUS DKK 92 MILLION YEAR AGO.GROWTH IN ALL REGIONS: EUROPE UP 8%, NORTH AMERICA UP 11% AND INTERNATIONAL MARKETS UP 198%..OUTLOOK FOR FREE CASH FLOW HAS BEEN REFINED..FREE CASH FLOW IS NOW EXPECTED AT DKK MINUS 400 MILLION OR BETTER.  Full Article

ALK-Abello's Paediatric Slit-Tablet Trial Meets Primary Endpoint
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - ALK-Abello A/S ::REG-LARGE-SCALE PAEDIATRIC SLIT-TABLET TRIAL MEETS PRIMARY ENDPOINT, CONFIRMING POTENTIAL IN CHILDREN.MAJOR REDUCTION IN AVERAGE TOTAL COMBINED SCORE (TCS) DURING PEAK RAGWEED SEASON OF 38%.PRIMARY ENDPOINT WAS MET.PRIMARY ENDPOINT WAS MET, WITH A MAJOR REDUCTION IN AVERAGE TOTAL COMBINED SCORE (TCS) DURING PEAK RAGWEED SEASON OF 38%.RESULTS WERE HIGHLY STATISTICALLY SIGNIFICANT (P<0.001).WILL NOW BEGIN DIALOGUE WITH RELEVANT REGULATORY AUTHORITIES ABOUT EXTENDING CURRENT PRODUCT LABELLING.EXPECTS TO PRESENT FURTHER DETAILS FROM TRIAL AT A SCIENTIFIC CONGRESS LATER IN 2019.FINDINGS OF CLINICALLY RELEVANT EFFICACY IN CHILDREN CONSISTENT WITH WHAT HAS BEEN DEMONSTRATED FOR SISTER PRODUCT, GRAZAX.  Full Article

ALK-Abello Q4 EBITDA Falls To DKK 61 Million
Tuesday, 6 Feb 2018 

Feb 6 (Reuters) - ALK-ABELLO A/S ::ALK RELEASES ITS ANNUAL REPORT 2017.Q4 TOTAL REVENUE DKK ‍763​ MILLION (REUTERS POLL: DKK 771 MILLION).Q4 ‍OPERATING PROFIT (EBITDA) WAS DKK 61 MILLION (96)​." ‍WE EXPECT DOUBLE-DIGIT REVENUE GROWTH FROM 2019 ONWARDS WITH NUMEROUS POTENTIAL UPSIDES"​.‍FULL-YEAR OUTLOOK IS IN LINE WITH PRELIMINARY OUTLOOK PRESENTED ON 4 DECEMBER 2017​.SALES OF LEGACY PRODUCTS WERE AFFECTED AS THE CAPACITY CONSTRAINTS CONTINUED TO LIMIT SALES‍​.  Full Article

ALK-Abello Provides Pricing In New Share Issue
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Alk-Abello A/S ALKb.CO::PRESS RELEASE PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S.PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S.- ON 11 DECEMBER 2017 ALK WILL ISSUE A TOTAL OF 92,076 NEW AA SHARES AND 920,760 NEW B SHARES AT DKK 690 PER SHARE.OFFERING RESULTING IN GROSS PROCEEDS FOR ALK IN THE AMOUNT OF DKK 698,856,840.  Full Article